Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
- PMID: 19366800
- PMCID: PMC3760276
- DOI: 10.1158/0008-5472.CAN-08-3884
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas
Abstract
Glioblastoma multiforme (GBM) are aggressive and uniformly fatal primary brain tumors characterized by their diffuse invasion of the normal-appearing parenchyma peripheral to the clinical imaging abnormality. Hypoxia, a hallmark of aggressive tumor behavior often noted in GBMs, has been associated with resistance to therapy, poorer survival, and more malignant tumor phenotypes. Based on the existence of a set of novel imaging techniques and modeling tools, our objective was to assess a hypothesized quantitative link between tumor growth kinetics [assessed via mathematical models and routine magnetic resonance imaging (MRI)] and the hypoxic burden of the tumor [assessed via positron emission tomography (PET) imaging]. Our biomathematical model for glioma kinetics describes the spatial and temporal evolution of a glioma in terms of concentration of malignant tumor cells. This model has already been proven useful as a novel tool to dynamically quantify the net rates of proliferation (rho) and invasion (D) of the glioma cells in individual patients. Estimates of these kinetic rates can be calculated from routinely available pretreatment MRI in vivo. Eleven adults with GBM were imaged preoperatively with (18)F-fluoromisonidazole (FMISO)-PET and serial gadolinium-enhanced T1- and T2-weighted MRIs to allow the estimation of patient-specific net rates of proliferation (rho) and invasion (D). Hypoxic volumes were quantified from each FMISO-PET scan following standard techniques. To control for tumor size variability, two measures of hypoxic burden were considered: relative hypoxia (RH), defined as the ratio of the hypoxic volume to the T2-defined tumor volume, and the mean intensity on FMISO-PET scaled to the blood activity of the tracer (mean T/B). Pearson correlations between RH and the net rate of cell proliferation (rho) reached significance (P < 0.04). Moreover, highly significant positive correlations were found between biological aggressiveness ratio (rho/D) and both RH (P < 0.00003) and the mean T/B (P < 0.0007).
Figures




Similar articles
-
Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma.Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):441-50. doi: 10.1007/s00259-010-1645-4. Epub 2010 Nov 12. Eur J Nucl Med Mol Imaging. 2011. PMID: 21072512 Clinical Trial.
-
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas.J Nucl Med. 2009 Jan;50(1):36-44. doi: 10.2967/jnumed.108.055467. Epub 2008 Dec 17. J Nucl Med. 2009. PMID: 19091885 Free PMC article.
-
Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.Math Med Biol. 2012 Mar;29(1):31-48. doi: 10.1093/imammb/dqr002. Epub 2011 May 11. Math Med Biol. 2012. PMID: 21562060 Free PMC article.
-
Usefulness of FMISO-PET for glioma analysis.Neurol Med Chir (Tokyo). 2013;53(11):773-8. doi: 10.2176/nmc.ra2013-0256. Epub 2013 Oct 29. Neurol Med Chir (Tokyo). 2013. PMID: 24172591 Free PMC article. Review.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.J Neurooncol. 2022 Jun;158(2):139-165. doi: 10.1007/s11060-021-03853-0. Epub 2021 Oct 25. J Neurooncol. 2022. PMID: 34694565
Cited by
-
Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.Magn Reson Imaging. 2012 Oct;30(8):1059-67. doi: 10.1016/j.mri.2012.04.026. Epub 2012 Aug 11. Magn Reson Imaging. 2012. PMID: 22884756 Free PMC article.
-
Patient-specific mathematical neuro-oncology: using a simple proliferation and invasion tumor model to inform clinical practice.Bull Math Biol. 2015 May;77(5):846-56. doi: 10.1007/s11538-015-0067-7. Epub 2015 Mar 21. Bull Math Biol. 2015. PMID: 25795318 Free PMC article. Review.
-
Current progress in patient-specific modeling.Brief Bioinform. 2010 Jan;11(1):111-26. doi: 10.1093/bib/bbp049. Epub 2009 Dec 2. Brief Bioinform. 2010. PMID: 19955236 Free PMC article. Review.
-
Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology.Cancer Res. 2011 Dec 15;71(24):7366-75. doi: 10.1158/0008-5472.CAN-11-1399. Epub 2011 Sep 7. Cancer Res. 2011. PMID: 21900399 Free PMC article.
-
To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer.Mol Imaging Biol. 2018 Dec;20(6):1061-1067. doi: 10.1007/s11307-018-1190-2. Mol Imaging Biol. 2018. PMID: 29623510
References
-
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96. - PubMed
-
- Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127–36. - PubMed
-
- Silbergeld DL, Rostomily RC, Alvord EC., Jr The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol. 1991;10:179–85. - PubMed
-
- Mankoff DA, Peterson LM, Tewson TJ, et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 2001;42:679–84. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical